Role of HIPEC In Ovarian Cancer

Friday, March 11, 2022

11:30 AM – 11:48 AM CST

Location: Coronado

Presenter(s)

Willemien van Driel, MD, PhD

gyne-oncologist
Antoni van Leeuwenhoek, Nederlands Kanker Instituut
Amsterdam, Netherlands

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:

Fabian M. Johnston, MD, MHS: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Deepa Magge, MD, FACS: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Willemien van Driel, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Olivier Glehen, MD, PhD: Gamida (Individual(s) Involved: Self): Consultant

Participants will be able 1. To provide an overview of evidence of CRS/HIPEC in ovarian and colorectal malignancies
2.To address limitations of study designs and better define important take-aways from these landmark randomized controlled trials

Olivier Glehen- Role of HIPEC in colorectal peritoneal metastases
Willemien J van Driel- Role of HIPEC in ovarian cancer

CME